ECTRIMS 2025

When Jill Blackburn’s daughter, Sierra, was diagnosed with pediatric multiple sclerosis (MS) at the age of 15, Blackburn had trouble finding sufficient support and resources. She eventually joined a relevant Facebook group, which she evolved into a nonprofit organization, the Pediatric Multiple Sclerosis Alliance. She now serves as…

Going through menopause with multiple sclerosis (MS) can be challenging, as the changes that come with this stage of life may interact or occur in tandem with existing MS symptoms. A team of researchers recently studied how menopause affects women living with MS, with their findings presented…

Roxy Murray was living up to being known as “The Multiple Sclerosis Fashionista” when she attended the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Barcelona, Spain, on a warm September afternoon. Murray, who has multiple sclerosis (MS) and lives in London, applies her…

The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted there. Nearly 10,000 people attended the 41st Congress of the European Committee for Treatment and Research in Multiple…

Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…

Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs of active inflammation in the brain, a group with limited treatment options. That’s according to new data…

Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in people with primary progressive multiple sclerosis (PPMS). That’s according to top-line data from the Phase 3b GAVOTTE…

Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…

Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with Gilenya (fingolimod), now the only MS therapy approved for pediatric patients in the U.S. That’s according to…